Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy ProQR Therapeutics N-V stock

Own ProQR Therapeutics N-V stock in just a few minutes.

ProQR Therapeutics N.V is a biotechnology business based in the US. ProQR Therapeutics N-V shares (PRQR) are listed on the NASDAQ and all prices are listed in US Dollars.

How to buy shares in ProQR Therapeutics N-V

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PRQR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

ProQR Therapeutics N-V share price

Use our graph to track the performance of PRQR stocks over time.

ProQR Therapeutics N-V shares at a glance

Information last updated 2021-03-25.
52-week range$3.60 - $7.54
50-day moving average $4.99
200-day moving average $4.60
Wall St. target price$23.92
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.31

Buy ProQR Therapeutics N-V shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy ProQR Therapeutics N-V stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ProQR Therapeutics N-V financials

Revenue TTM $11.3 million
Gross profit TTM $9.5 million
Return on assets TTM -24.49%
Return on equity TTM -62%
Profit margin 0%
Book value $1.36
Market capitalisation $462.9 million

TTM: trailing 12 months

Shorting ProQR Therapeutics N-V shares

There are currently 1.2 million ProQR Therapeutics N-V shares held short by investors – that's known as ProQR Therapeutics N-V's "short interest". This figure is 29.3% up from 899,379 last month.

There are a few different ways that this level of interest in shorting ProQR Therapeutics N-V shares can be evaluated.

ProQR Therapeutics N-V's "short interest ratio" (SIR)

ProQR Therapeutics N-V's "short interest ratio" (SIR) is the quantity of ProQR Therapeutics N-V shares currently shorted divided by the average quantity of ProQR Therapeutics N-V shares traded daily (recently around 430674.07407407). ProQR Therapeutics N-V's SIR currently stands at 2.7. In other words for every 100,000 ProQR Therapeutics N-V shares traded daily on the market, roughly 2700 shares are currently held short.

However ProQR Therapeutics N-V's short interest can also be evaluated against the total number of ProQR Therapeutics N-V shares, or, against the total number of tradable ProQR Therapeutics N-V shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ProQR Therapeutics N-V's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 ProQR Therapeutics N-V shares in existence, roughly 20 shares are currently held short) or 0.0287% of the tradable shares (for every 100,000 tradable ProQR Therapeutics N-V shares, roughly 29 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against ProQR Therapeutics N-V.

Find out more about how you can short ProQR Therapeutics N-V stock.

ProQR Therapeutics N-V share dividends

We're not expecting ProQR Therapeutics N-V to pay a dividend over the next 12 months.

ProQR Therapeutics N-V share price volatility

Over the last 12 months, ProQR Therapeutics N-V's shares have ranged in value from as little as $3.6 up to $7.54. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ProQR Therapeutics N-V's is 0.4626. This would suggest that ProQR Therapeutics N-V's shares are less volatile than average (for this exchange).

ProQR Therapeutics N-V overview

ProQR Therapeutics N. V. , a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase 1/2 stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase 1/2 aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy. It has a license agreement with General Hospital Corporation, Radboud University Medical Center, Inserm Transfert SA, and Leiden University Medical Center. ProQR Therapeutics N. V.

Frequently asked questions

What percentage of ProQR Therapeutics N-V is owned by insiders or institutions?
Currently 2.949% of ProQR Therapeutics N-V shares are held by insiders and 69.26% by institutions.
When does the fiscal year end for ProQR Therapeutics N-V?
ProQR Therapeutics N-V's fiscal year ends in December.
Where is ProQR Therapeutics N-V based?
ProQR Therapeutics N-V's address is: Zernikedreef 9, Leiden, Netherlands, 2333 Ck
What is ProQR Therapeutics N-V's ISIN number?
ProQR Therapeutics N-V's international securities identification number is: NL0010872495
What is ProQR Therapeutics N-V's CUSIP number?
ProQR Therapeutics N-V's Committee on Uniform Securities Identification Procedures number is: N71542109

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site